Vaxcyte shares surge as pneumococcal vaccine meets main trial goals
Vaxcyte said on Monday its experimental pneumococcal vaccine met its main goals in a late-stage study in adults aged 50 and older, sending its shares up 91% before the bell.
Vaxcyte said on Monday its experimental pneumococcal vaccine met its main goals in a late-stage study in adults aged 50 and older, sending its shares up 91% before the bell.